339 309

Cited 8 times in

Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium

DC FieldValueLanguage
dc.contributor.author박효진-
dc.contributor.author이용찬-
dc.contributor.author최창환-
dc.date.accessioned2015-01-06T16:40:04Z-
dc.date.available2015-01-06T16:40:04Z-
dc.date.issued2014-
dc.identifier.issn2093-0879-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98534-
dc.description.abstractBACKGROUND/AIMS: Antispasmodics such as octylonium are widely used to manage irritable bowel syndrome (IBS) symptoms. However, the efficacy and safety of another antispasmodic, tiropramide, remain uncertain. We aimed to evaluate the efficacy and safety of tiropramide compared with octylonium in patients with IBS. METHODS: In this multicenter, randomized, non-inferiority trial, 287 patients with IBS (143 receiving tiropramide and 144 octylonium) were randomly allocated to either tiropramide 100 mg or octylonium 20 mg t.i.d (means 3 times a day) for 4 weeks. Primary endpoint was the mean change of abdominal pain from baseline assessed by visual analogue scales (VAS) score after 4 weeks of treatment. Secondary endpoints were the changes in abdominal pain from baseline at week 2 and in abdominal discomfort at weeks 2 and 4, using VAS scores, patient-reported symptom improvement including stool frequency and consistency, using symptom diaries, IBS-quality of life (IBS-QoL), and depression and anxiety, at week 4. RESULTS: The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference,-0.26 mm; 95% CI,-4.33-3.82; P = 0.901). Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ. The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed. CONCLUSIONS: Tiropramide is as effective as octylonium in managing abdominal pain in IBS, with a similar safety profile.-
dc.description.statementOfResponsibilityopen-
dc.format.extent113~121-
dc.relation.isPartOfJOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleEfficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorKang Nyeong Lee-
dc.contributor.googleauthorOh Young Lee-
dc.contributor.googleauthorMyung-Gyu Choi-
dc.contributor.googleauthorChong Il Sohn-
dc.contributor.googleauthorKyu Chan Huh-
dc.contributor.googleauthorKyung Sik Park-
dc.contributor.googleauthorJoong Goo Kwon-
dc.contributor.googleauthorNayoung Kim-
dc.contributor.googleauthorPoong-Lyul Rhee-
dc.contributor.googleauthorSeung-Jae Myung-
dc.contributor.googleauthorJoon Seong Lee-
dc.contributor.googleauthorKwang Jae Lee-
dc.contributor.googleauthorHyojin Park-
dc.contributor.googleauthorYong Chan Lee-
dc.contributor.googleauthorSuck Chei Choi-
dc.contributor.googleauthorHye-Kyung Jung-
dc.contributor.googleauthorSam Ryong Jee-
dc.contributor.googleauthorChang Hwan Choi-
dc.contributor.googleauthorGwang Ha Kim-
dc.contributor.googleauthorMoo In Park-
dc.contributor.googleauthorIn Kyung Sung-
dc.identifier.doi10.5056/jnm.2014.20.1.113-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01774-
dc.contributor.localIdA02988-
dc.contributor.localIdA04201-
dc.relation.journalcodeJ01623-
dc.identifier.eissn2093-0887-
dc.identifier.pmid24466452-
dc.subject.keywordAntispasmodic-
dc.subject.keywordIrritable bowel syndrome-
dc.subject.keywordOctylonium-
dc.subject.keywordRome III criteria-
dc.subject.keywordTiropramide-
dc.contributor.alternativeNamePark, Hyo Jin-
dc.contributor.alternativeNameLee, Yong Chan-
dc.contributor.alternativeNameChoi, Chang Hwan-
dc.contributor.affiliatedAuthorPark, Hyo Jin-
dc.contributor.affiliatedAuthorLee, Yong Chan-
dc.contributor.affiliatedAuthorChoi, Chang Hwan-
dc.citation.volume20-
dc.citation.number1-
dc.citation.startPage113-
dc.citation.endPage121-
dc.identifier.bibliographicCitationJOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, Vol.20(1) : 113-121, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.